

Technology Advisory Committee C Interests Register

Mosunetuzumab for treating relapsed or refractory follicular lymphoma [ID3931]

Publication Date: 31/05/2023

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Michael Chambers	Committee member	Direct financial	Mr Chambers has coordinated a training programme with the University of Utrecht on Real World Evidence for Roche. This did not include any consideration of Roche products. He has also attended an advisory board for Pfizer in an unrelated disease area (prostate cancer).	N/A	14/11/2022	N/A	It was agreed that his declaration would not prevent Mr Chambers from participating in discussions on this appraisal.
Dr Richard Nicholas	Committee member	Direct financial	Dr Nicholas has attended paid advisory boards with Roche in an unrelated disease area (Multiple Sclerosis).	N/A	22/11/2022	N/A	It was agreed that his declaration would not prevent Dr Nicholas from participating in discussions on this appraisal.
Dr Kim Linton	Clinical expert	Direct financial	Dr Linton declared a financial interest as she has received	N/A	24/03/2022	N/A	It was agreed that her declaration would not

			financial remuneration from Celgene, Beigene, Roche, Kite/Gilead, and Genmab for advisory board work.				prevent Dr Linton from providing expert advice to the committee.
Dr Mark Bishton	Clinical expert	Direct financial	Dr Bishton received remuneration for attending an advisory board for Roche in 2022 and travel expenses for a conference with Roche. He was also a PI on two clinical studies involving mosunetuzumab.	N/A	11/06/2022	N/A	It was agreed that his declaration would not prevent Dr Bishton from providing expert advice to the committee.